Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Browse trials for

• Coronary Artery Disease 5,580
• Coronary Disease 2,836

Keywords

• coronary disease
• drug eluting stent

Study population

Groups and cohorts

• DESSIAN

  consecutive patients receiving CYPHER stent

• K-XIENCE

  consecutive patients receiving Xience stent

• GENOUS

  consecutive patients receiving GENOUS stent

• ELEMENT

  consecutive patients receiving PROMUS-ELEMENT stent

• PRIME

  consecutive patients receiving XIENCE-PRIME stent

• NOBORI

  consecutive patients receiving NOBORI stent

• INTEGRITY

  consecutive patients receiving RESOLUTE-INTEGRITY stent

• XPEDITION

  consecutive patients receiving XIENCE-XPEDITION stent

• BIOMATRIX

  consecutive patients receiving BIOMATRIX stent

• CILOTAX

  consecutive patients receiving CILOTAX stent

• DEB

  consecutive patients receiving Drug eluting balloon

• DESYNE

  consecutive patients receiving DESYNE stent

• PREMIER

  consecutive patients receiving PROMUS-PREMIER stent

• ORSIRO

  consecutive patients receiving ORSIRO stent

• ONYX

  consecutive patients receiving ONYX stent

• BVS

  consecutive patients receiving Bioresorbable Vascular Scaffold

• BVS AMI

  consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold

• Ultimaster

  consecutive patients receiving Ultimaster stent

• Synergy

  consecutive patients receiving Synergy stent

• Biofreedom

  consecutive patients receiving Biofreedom stent

• Firehawk

  consecutive patients receiving Firehawk stent

• DESyne X2

  consecutive patients receiving DESyne X2 stent

• Sierra

  consecutive patients receiving Sierra stent

• Tansei

  consecutive patients receiving Tansei stent

• Synergy XD and Synergy Megatron™

  consecutive patients receiving Synergy XD or Synergy Megatron™ stent

• Xience-Skypoint

  consecutive patients receiving Xience-Skypoint stent

• Coroflex ISAR NEO

  consecutive patients receiving Coroflex ISAR NEO stent

Primary outcomes

1. Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)

   Time frame: at 12 months post procedure

Secondary outcomes

1. Death (all-cause and cardiac)

   Time frame: at 12 months and annually up to 5 years

2. Myocardial infarction

   Time frame: at 12 months and annually up to 5 years

3. Stent thrombosis

   Time frame: at 12 months and annually up to 5 years

4. Target-lesion and target-vessel revascularization

   Time frame: at 12 months and annually up to 5 years

5. Stroke

   Time frame: at 12 months and annually up to 5 years

6. Procedural success

   Time frame: at 1 day

Publications

• Kim TO, Kang DY, Ahn JM, Kim MJ, Lee PH, Kim H, Choi Y, Lee J, Lee JM, Jo HH, Park YS, Lim SM, Park SJ, Park DW. Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease. JACC Cardiovasc Interv. 2024 Jan 8;17(1):32-42. doi: 10.1016/j.jcin.2023.10.068. PubMed 38199751 ↗
• Jeong YJ, Hyun J, Lee J, Kim JH, Yang Y, Choe K, Lee JS, Park H, Cho SC, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures. JACC Asia. 2022 Mar 1;2(2):182-193. doi: 10.1016/j.jacasi.2021.10.008. eCollection 2022 Apr. PubMed 36339122 ↗
• Yang Y, Hyun J, Lee J, Kim JH, Lee JB, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus. JACC Asia. 2021 Sep 21;1(2):173-184. doi: 10.1016/j.jacasi.2021.07.009. eCollection 2021 Sep. PubMed 36338165 ↗
• Park S, Ahn JM, Kim TO, Park H, Cho SC, Kang DY, Lee PH, Park DW, Park SJ; IRIS-DES Registry Investigators. Incidence and Impact of Thrombocytopenia in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 Nov 1;134:55-61. doi: 10.1016/j.amjcard.2020.07.059. Epub 2020 Aug 16. PubMed 32891400 ↗
• Park H, Ahn JM, Kang DY, Lee JB, Park S, Ko E, Cho SC, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1403-1413. doi: 10.1016/j.jcin.2020.03.023. Epub 2020 May 27. PubMed 32473888 ↗
• Lee CH, Ahn JM, Lee KS, Kang DY, Lee PH, Lee SW, Lee CW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Prevalence, predictors, prognostic significance, and effect of techniques on outcomes of coronary lesion calcification following implantation of drug-eluting stents: a patient-level pooled analysis of stent-specific, multicenter, prospective IRIS-DES registries. Coron Artery Dis. 2021 Jan;32(1):42-50. doi: 10.1097/MCA.0000000000000896. PubMed 32310851 ↗
• Lee CH, Kang DY, Han M, Hur SH, Rha SW, Her SH, Seung KB, Kim KS, Lee PH, Ahn JM, Lee SW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019 May 1;282:17-23. doi: 10.1016/j.ijcard.2019.01.108. Epub 2019 Feb 2. PubMed 30745256 ↗
• Lee PH, Kwon O, Ahn JM, Lee CH, Kang DY, Lee JB, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. J Am Coll Cardiol. 2018 Feb 27;71(8):832-841. doi: 10.1016/j.jacc.2017.12.032. PubMed 29471933 ↗

Individual participant data

Plan to share: Undecided